Alexis Matralis Research Group

1) Water-soluble Stoichiometric Polyelectrolyte Complexes Based on Cationic Comb-Type Copolymers. Alexios Matralis, Maria Sotiropoulou, George Bokias and George Staikos. Macromol. Chem. Phys., 2006, 207, 1018-1025 (

2) Hypolipidemic and Antioxidant Properties of Novel Squalene Synthase Inhibitors. Alexios Matralis and Angeliki Kourounakis. Review of Clinical Pharmacology and Pharmacokinetics, 2008, 22, 238-240 (

3) Antioxidant Activity of Newly Synthesized 2,7-Diazaphenothiazines. Beata Morak-MІodawska, Krystian Pluta, Alexios N. Matralis and Angeliki P. Kourounakis. Arch. Pharm. Chem. Life Sci., 2010, 343, 268-273 (

4) Design of More Potent Squalene Synthase Inhibitors with Multiple Activities. Angeliki P. Kourounakis, Alexios N. Matralis, Anastasios Nikitakis. Bioorg. Med. Chem., 2010, 18, 7402-7412 (

5) Novel Benzoxazine and Benzothiazine Derivatives as Multifunctional Antihyperlipidemic Agents. Alexios N. Matralis, Maria G. Katselou, Anastasios Nikitakis and Angeliki P. Kourounakis. J. Med. Chem., 2011, 54, 5583-5591 (

6) Squalene Synthase Inhibitors: An Update on the Search for New Antihyperlipidemic and Antiatherosclerotic Agents. Angeliki P. Kourounakis, Maria G. Katselou, Alexios N. Matralis, Eleni M. Ladopoulou and Eugenia Bavavea. Curr. Med. Chem., 2011, 18, 4418-4439. (

7) New Multifunctional di-tert-butyl-phenol-octahydro(pyrido/benz)oxazine Derivatives with Antioxidant, Antihyperlipidemic and Antidiabetic Action. Eleni M. Ladopoulou, Alexios N. Matralis and Angeliki P. Kourounakis. J. Med. Chem., 2013, 56, 3330-3338 (

8) Design of Novel Potent Antihyperlipidemic Agents with Antioxidant/Anti-inflammatory Properties. Exploiting Phenothiazine’s Strong Antioxidant Activity. Alexios N. Matralis and Angeliki P. Kourounakis. J. Med. Chem., 2014, 57, 2568-2581. Highlighted by SciBX (March 2014, vol. 7, issue 11) (

9) Multi-targeted Drug Design Approaches for Multifactorial Diseases: from Neurodegenerative to Cardiovascular Applications. Maria Katselou, Alexios N. Matralis and Angeliki P. Kourounakis. Curr. Med. Chem., 2014, 21, 2743-2787 (

10) Human Isoprenoid Synthase Enzymes as Therapeutic Targets. Jaeok Park, Alexios N. Matralis, Albert M. Berghuis and Youla S. Tsantrizos. Frontiers in Chemistry, 2014, 2, 1-21 (

11) Evaluation of two Novel Antioxidants with Differential Effects on Curcumin-induced Apoptosis in C2 Skeletal Myoblasts; Involvement of JNKs. Maria Peleli, Ioanna-Katerina Aggeli, Alexios N. Matralis,# Angeliki P. Kourounakis, Isidoros Beis and Catherine Gaitanaki. Bioorg. Med. Chem., 2015, 23, 390-400 (# second author due to equal contribution of the first two authors), (

12) Antihyperlipidemic Morpholine Derivatives with Antioxidant Activity: An Investigation of the Aromatic Substitution. Eleni M. Ladopoulou, Alexios N. Matralis, Anastasios Nikitakis and Angeliki P. Kourounakis. Bioorg. Med. Chem., 2015, 23, 7015-7023 (

13) Synthesis of Benzothiophene-containing 10- and 11-Member Cyclic Phostones. Alexios N. Matralis and Youla S. Tsantrizos. Eur. J. Org. Chem., 2016 (22), 3728-3736 (

14) Balancing Antioxidant, Hypolipidemic and Anti-inflammatory Activity in a Single Agent: The Example of 2-Hydroxy-2-Substituted Morpholine, 1,4-Benzoxazine and 1,4-Benzothiazine Derivatives as a Potential Therapeutic Approach against Atherosclerosis. Alexios N. Matralis, Eugenia-Ismini Bavavea, Sandra Incerpi, Jens Z. Pedersen and Angeliki P. Kourounakis. Curr. Med. Chem., 2017, 24, 1214-1227 (

15) Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase. Jaeok Park, Chun Y. Leung, Alexios N. Matralis,# Cyrus Lacbay, Michail Tsakos, Guillermo Fernandez De Troconiz, Albert Berghuis and Youla S. Tsantrizos. J. Med. Chem., 2017, 60, 2119-2134 (# second author due to equal contribution of the first two authors), (

16) Developing Potential Agents against Atherosclerosis: Design, Synthesis and Pharmacological Evaluation of Novel Dual Inhibitors of Oxidative Stress and Squalene Synthase Activity. Maria Katselou, Alexios N. Matralis and Angeliki P. Kourounakis. Eur. J. Med. Chem., 2017, 138, 748-760 (

17) Molecular Tools that Block Maturation of the Nuclear Lamin A and Decelerate Cancer Cell Migration. Alexios N. Matralis, Dimitrios Xanthopoulos, Geneviève Huot, Stéphane Lopes-Paciencia, Charles Cole, Hugo de Vries, Gerardo Ferbeyre and Youla S. Tsantrizos. Bioorg. Med. Chem., 2018, 26, 5547-5554 (

18) Development and Therapeutic Potential of Autotaxin Small Molecule Inhibitors. From Bench to Advanced Clinical Trials. Alexios N. Matralis,* Antreas Afantitis and Vassilis Aidinis.* In Press, Med. Res. Rev., 2018 (* corresponding authors), (

19) Optimization of the Pharmacological Profile of Bifunctional Antihyperlipidemic/Antioxidant Morpholine Derivatives by Focusing on the Squalene Synthase Inhibitory Activity. Alexios N. Matralis and Angeliki P. Kourounakis., Med. Chem. Lett., 2019, 10, 98-104 (

20) Development of Chemical Entities Endowed with Potent Fast-killing Properties against Plasmodium falciparum Malaria Parasites. Alexios N. Matralis,* Adnan Malik, Maria Penzo, Inmaculada Moreno, Maria J. Almela, Isabel Camino, Begnino Crespo, Anas Saadeddin, Sonja Ghidelli-Disse, Lurdes Rueda, Félix Calderón, Simon A. Osborne, Gerald Drewes, Markus Böesche, Elena Fernández-Álvaro, José Ignacio Martín Hernando, David A. Baker.* J. Med. Chem., 2019, 62, 9217-9235 (* corresponding authors), (

21) Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors. Christiana Magkrioti, Eleanna Kaffe, Elli-Anna Stylianaki, Camelia Sidahmet, Georgia Melagraki, Antreas Afantitis, Alexios N. Matralis,* Vassilis Aidinis.* Int. J. Mol. Sci., 2020, 21, 7002-7018 (* corresponding authors), (

22) Targeting Malaria Parasite cGMP Signalling to Develop New Drugs. David A. Baker, Alexios N. Matralis, Simon A. Osborne, Jonathan M. Large, Maria Penzo. Front. Microbiol., 2020, In Press (

23) Commonalities between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Konstantinos Ntatsoulis, Theodoros Karampitsakos, Eliza Tsitoura, Elli-Anna Stylianaki, Alexios N. Matralis, Argyrios Tzouvelekis, Katerina Antoniou, Vassilis Aidinis. Front. Immunol., 2021, 12, article687397, (

24) Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase. Hiu-Fang Lee, Cyrus M. Lacbay, Rebecca Boutin, Alexios N. Matralis, Jaeok Park, Daniel D. Waller, Tian Lai Guan, Michael Sebag and Youla S. Tsantrizos. J. Med. Chem., 2022, 65, 2471-2496, (

25) “Hit” to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors. Elli-Anna Stylianaki, Christiana Magkrioti, Eleni M. Ladopoulou, Konstantinos D. Papavasileiou, Panagiotis Lagarias, Georgia Melagraki, Martina Samiotaki, George Panayotou, Skarlatos G. Dedos, Antreas Afantitis, Vassilis Aidinis,* Alexios N. Matralis.* (*corresponding authors), Eur. J. Med. Chem., 2022, 249, article 115130, (

26) Repurposing the antipsychotic drug Amisulpride for targeting synovial fibroblast activation in arthritis. Dimitra Papadopoulou, Fani Roumelioti, Christos Tzaferis, Panagiotis Chouvardas, Anna-Kathrine Pedersen, Filippos Charalampous, Eleni Christodoulou-Vafeiadou, Lydia Ntari, Niki Karagianni, Maria C. Denis, Jesper V. Olsen, Alexios N. Matralis and George Kollias. JCI Insight, 2023, 8, article e165024 (

27) Effect of a new Squalene Synthase inhibitor on an ApoE-/- mouse model of atherosclerosis. Alexios N. Matralis,* Loukas Kaklamanis, Despina Perrea, Angeliki Kourounakis.* (*corresponding authors), Bioorg. Med. Chem., 2023, 90, article 117378 (


1) Thieno[3,4-c]pyrazol-3-yl acetamides as novel Autotaxin inhibitors. Alexios N. Matralis and Vassilis Aidinis. Patent No: WO2022/003377 A1.
2) Anti-inflammatory Carboxamide Derivatives. George Kollias, Niki Karagianni, Maria Denis, Alexios N. Matralis, Dimitra Papadopoulou, Eleni Karkoulia. Patent No: WO2022/189636 A1.